AQST Deadline: AQST Investors Have Opportunity to Lead Aquestive Therapeutics, Inc. Securities Fraud Lawsuit
NEW YORK, May 3, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, remind…
prnewswire.com

Intelligence analysis not yet available for this stock. Full AI-powered analysis may be available on the intelligence page.
Analyst consensus estimates · Actuals replace estimates as reported
| Year | Revenue Est. | Rev Gth | EPS Est. | EPS Gth | Range | Analysts |
|---|---|---|---|---|---|---|
FY2024 | $259.4M $251.9M–$266.8M | — | $0.18 | — | ±4% | Low1 |
FY2025 | $266.3M $257.9M–$274.7M | ▲ +2.7% | -$0.04 | — | ±4% | Moderate3 |
FY2026(current) | $211.8M $205.7M–$217.9M | ▼ -20.5% | -$0.12 | — | ±2% | Low1 |
Dividend per payment — last 8 periods
NEW YORK, May 3, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, remind…

No company information available
| Symbol | Price | Day % | Mkt Cap↓ | P/E | Rev Grw | Margin | ELO |
|---|---|---|---|---|---|---|---|
AHRT◀ | — | -0.16% | — | — | — | — | — |
| $216.91 | -0.20% | $153.1B | 107.8 | +3582.4% | 878.3% | 1511 | |
| $141.41 | -0.43% | $131.8B | 35.4 | +717.6% | 3880.1% | 1505 | |
| $1085.70 | +0.20% | $107.0B | 75.1 | +585.3% | 1457.9% | 1524 | |
| $181.61 | -0.60% | $84.6B | 29.4 | +511.4% | 2376.5% | 1491 | |
| $200.70 | -0.12% | $69.0B | 50.3 | +1004.0% | 2140.8% | 1518 | |
| $202.44 | -0.62% | $65.8B | 14.3 | +671.9% | 7251.1% | 1507 | |
| Sector avg | — | -0.28% | — | 52.1 | +1178.8% | 2997.4% | 1509 |